Immuno-oncology, Pre-clinical

Backed with $180M-plus in cash, I/O trailblazer Lieping Chen spotlights NextCure’s preclinical work on next-gen antibody

Right on the heels of nailing a $40 million upfront for its oncology R&D collaboration deal with Eli Lilly and bringing its tally of cash raised to $180 million with an ambitious venture round, Yale spinout NextCure has laid the scientific foundation for the immuno-oncology company in a new preclinical study just published in Nature Medicine.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,800+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,800+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->